Untitled
Previous | Next

Back to BW50
Home Page >>

The BusinessWeek 50 Ranking

9

Amgen

AMGEN MAY BE ONE of the grandpas of the biotech industry, but it’s looking as sprightly as ever. Profits jumped 55% last year on strong sales of its flagship drugs to treat anemia and to prevent chemotherapyinduced infections. Unlike many of its Big Pharma cousins, the California company is adept at balancing its investments in marketing and research, allowing it to boost sales of existing drugs while developing promising new treatments, such as those for colon cancer and osteoporosis. Will Amgen’s constitution stay strong? Analysts predict a 15% annual rate of growth in earnings over the next five years.

Company Info

2005 Rank

106

GET MORE
COMPANY INFO

AMGN

Market Value
$ Million

92,387.5

Total Return
$ Million
(1-yr.) 22.5
(3-yr.) 38.1
2005 Sales
$ Billion

12.4

Sales Growth
$ Million
(1-yr.) 18
(3-yr.) 30.6
Long-Term Growth Est. %

15.0

Net income
$ Million

3,674.0

Net Income Growth
$ Million
(1-yr.) 55
(3-yr.) 27.5
Net Margin %*

29.6

Return on Inv. Capital (%)*

16.2

Share Price
12-Mo. Hi/Lo

87/56

P/E Ratio

26

Industry Pharmaceuticals & Biotechnology
CORPORATE WEB SITE
More in S&P 500 Companies Scoreboard >
*Trailing 12 months
Company data as of 2/28/06 provided by Standard & Poor's Compustat

Kevin Sharer

Kevin Sharer, 58

CEO since 2000




More BW Stories on Amgen